Sergei Gryaznov
Hoofd Techniek/Wetenschap/O&O bij MAIA BIOTECHNOLOGY, INC.
Vermogen: 119 289 $ op 30-04-2024
Profiel
Sergei M.
Gryaznov is the founder of Lynx Therapeutics, Inc. (founded in 1993).
He is currently the Chief Scientific Officer at MAIA Biotechnology, Inc. (since 2019).
Dr. Gryaznov previously worked as the Chemistry Director at Geron Corp.
(from 1998 to 2013) and as the Chief Technology Officer at Exicure Operating Co. Dr. Gryaznov holds graduate and doctorate degrees from Moscow State University Lomonosov.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
MAIA BIOTECHNOLOGY, INC.
0.22% | 26-04-2024 | 44 511 ( 0.22% ) | 119 289 $ | 30-04-2024 |
Actieve functies van Sergei Gryaznov
Bedrijven | Functie | Begin |
---|---|---|
MAIA BIOTECHNOLOGY, INC. | Hoofd Techniek/Wetenschap/O&O | 01-12-2019 |
Eerdere bekende functies van Sergei Gryaznov
Bedrijven | Functie | Einde |
---|---|---|
GERON CORPORATION | Corporate Officer/Principal | 01-01-2013 |
Lynx Therapeutics, Inc.
Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Corporate Officer/Principal | 01-01-1997 |
Exicure Operating Co.
Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Sergei Gryaznov
Moscow State University Lomonosov | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
GERON CORPORATION | Health Technology |
MAIA BIOTECHNOLOGY, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Exicure Operating Co.
Exicure Operating Co. Pharmaceuticals: MajorHealth Technology Exicure Operating Co. operates as a biopharmaceutical company commercializing spherical nucleic acid constructs as gene regulation and modulation agents for diseases including applications in oncology, dermatology, neurology, and for immune disorders. The SNA constructs allow the use of oligonucleotide-based therapies to treat diseases in a range of tissue types. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL. | Health Technology |
Lynx Therapeutics, Inc.
Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Lynx Therapeutics, Inc. was a developer of genetic analysis products for the pharmaceutical, biotechnology and agriculture industries. It's MPSSTM instruments analyze millions of DNA molecules in parallel enabling genome structure characterization at an unprecedented level of resolution. MPSSTM provides comprehensive and quantitative digital information important to modern systems biology research in the pharmaceutical, biotechnology and agricultural industries. The company was headquartered in Hayward, CA. | Health Technology |